396074-50-3

Basic information

• Product Name: (s)-tert-butyl 5-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide
• Synonyms: (s)-tert-butyl 5-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide;(S)-3-Boc-5-methyl-1,2,3-oxathiazolidine 2,2-dioxide;tert-butyl (5S)-5-methyl-2,2-dioxo-1,2λ,3-oxathiazolidine-3-carboxylate;tert-Butyl (5S)-5-methyl-2,2-dioxo-oxathiazolidine-3-carboxylate;(5S)-2,2-DIOXIDO-5-METHYL-1,2,3-OXATHIAZOLIDINE, N-BOC PROTECTED
• CAS NO: 396074-50-3
• Molecular Formula: C₈H₁₅NO₅S
• Molecular Weight: 237.2734
• Mol File: 396074-50-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (s)-tert-butyl 5-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide(CAS DataBase Reference)
• NIST Chemistry Reference: (s)-tert-butyl 5-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide(396074-50-3)
• EPA Substance Registry System: (s)-tert-butyl 5-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide(396074-50-3)

Safety Data

• Hazardous Substances Data: 396074-50-3(Hazardous Substances Data)

Usage

General Description

"(s)-tert-butyl 5-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide" is a chemical compound with the molecular formula C10H17NO5S. It is a derivative of 1,2,3-oxathiazolidine-2,2-dioxide and is commonly used as a building block in organic synthesis. (s)-tert-butyl 5-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide has potential applications in pharmaceuticals and agrochemicals due to its diverse chemical properties. It can serve as a precursor for the synthesis of various drugs and functional molecules. The tert-butyl group in the compound enhances its stability and reactivity, making it a valuable intermediate in organic chemistry. Additionally, the presence of the 1,2,3-oxathiazolidine-3-carboxylate moiety in the molecule gives it potential pharmacological activity for further exploration in medicinal research.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 167938-56-9 tert-butyl [(2S)-2-hydroxypropyl]carbamate 

Downstream Products

• 1338090-92-8 [(S)-2-(3-trifluoromethylphenyl)propyl]carbamic acid tert-butyl ester 

Relevant articles and documents

Pyrizolo[1,5-a]pyrimidine derivatives of the second-generation TRK inhibitor: Design, synthesis and biological evaluation

As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key drug target in solid tumors. However, the use of the First-generation Trk inhibitors was greatly restricted due to mutant drug resistance. Fortunately, the emergence of the Second-generation of Trk inhibitors has brought an effective solution to this mutant resistance, such as TPX-0005 (Repotrectinib). Here, we reported a series of pyrizolo[1,5-a]pyrimidine derivatives as the second-generation Trk inhibitors, and carried out the subsequent biological activity evaluation. Among them, the best compound 14h (IC50 = 1.40, 1.80 nM, against TrkA, TrkAG595R, respectively) and 14j (IC50 = 0.86, 6.92 nM, against TrkA, TrkAG595R, respectively) has a kinase activity comparable to TPX-0005, and 14j (IC50 = 350 nM against ALK) has a higher selectivity of Trk inhibition than TPX-0005, which may be of great significance for reducing toxicity.

SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE

Provided herein are solid forms, salts such as compound B, and formulations of 3-((lR,3R)-l-(2,6-difluoro-4-((l-(3-fluoropropyl) azetidin-3-yl)amino)phenyl)-3-methyl-l,3,4,9-tetrahydro-2H- pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-l-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.

HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.